Mildronate capsules 500 mg 60 pcs
Condition: New product
961 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Meldonius
Release form
Capsules
Composition
Meldonium dihydrate 500 mg Auxiliary substances: potato starch - 27.2 mg, colloidal silicon dioxide - 10.8 mg, calcium stearate - 5.4 mg. The composition of the capsule shell: titanium dioxide (E171) - 2%, gelatin - 98%. 10 pieces. - contour cell packages (6) - cardboard packs.
Pharmacological effect
A drug that improves metabolism and energy supply of tissues. Meldonium dihydrate is a synthetic analogue of gamma-butyrobetaine, a substance that is found in every cell of the human body. The mechanism of action determines the diversity of its pharmacological effects: increasing efficiency, reducing the symptoms of mental and physical overstrain, activation of tissue and humoral immunity, cardioprotective effect. Inhibits gamma-butyrobetaine hydroxinase, reduces carnitine synthesis and transport of long-chain fatty acids through cell walls, prevents accumulation of activated forms of unoxidized fatty acids - derivatives of acylcarnitine and acylcoenzyme A. in cells. violation of ATP transport; at the same time, it activates glycolysis, which proceeds without additional consumption of oxygen. As a result of reducing the concentration of carnitine, gamma-butyrobetaine with vasodilating properties is intensively synthesized. It has a cardioprotective effect, normalizes myocardial metabolism. In acute ischemic myocardial damage, meldonium slows down the formation of a necrotic zone, shortens the rehabilitation period. In heart failure, the drug increases myocardial contractility, increases exercise tolerance, reduces the frequency of strokes. In acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the ischemic focus, promotes the redistribution of blood in favor of the ischemic area. Effective with vascular and dystrophic pathology of the fundus. It has a tonic effect on the central nervous system, eliminates functional disorders of the somatic and autonomic nervous system in patients with chronic alcoholism with withdrawal syndrome.
Pharmacokinetics
Absorption: After oral administration, Meldonium dihydrate is rapidly absorbed from the gastrointestinal tract. Bioavailability is 78%. Cmax in plasma is achieved within 1-2 hours after ingestion. Metabolism and excretion: Metabolized mainly in the liver to form two major metabolites that are excreted by the kidneys. T1 / 2 when taken orally is 3-6 hours and depends on the dose.
Indications
As part of complex treatment of coronary artery disease (angina, myocardial infarction), chronic heart failure, dyshormonal cardiomyopathy. As part of complex therapy of subacute and chronic cerebral circulation disorders (stroke and cerebrovascular insufficiency). Reduced performance. Physical and physical overpump athletes). Abstinence syndrome in chronic alcoholism (in combination with a specific therapy of alcoholism).
Contraindications
Increased intracranial pressure (including in violation of the venous outflow, intracranial tumors). Age up to 18 years (efficacy and safety have not been established). Pregnancy. Lactation period (breastfeeding). Hypersensitivity to the active substance and other components of the drug. With caution should use the drug for diseases of the liver and / or kidneys.
Precautionary measures
With caution should use the drug for diseases of the liver and / or kidneys.
Use during pregnancy and lactation
The safety of the drug during pregnancy has not been established. In order to avoid possible adverse effects on the fetus, Mildronate should not be given during pregnancy. It is not known whether meldonium dihydrate is excreted in breast milk. If necessary, the use of the drug Mildronate during lactation breastfeeding should be discontinued.
Dosage and administration
In connection with the possibility of an exciting effect, the drug is recommended to be used in the first half of the day and no later than 17.00 (when taken several times a day). In IHD (stenocardia, myocardial infarction), chronic heart failure in the complex therapy, the drug is administered orally at a dose of 0.5-1 g / day, the frequency of application is 1-2 times / day. The course of treatment is 4-6 weeks. In case of dyshormonal cardiomyopathy, Mildronate, as part of complex therapy, is administered orally at 500 mg / day. The course of treatment is 12 days.With subacute cerebral blood flow disorders (stroke and cerebrovascular insufficiency), after completing the course of injection therapy with the drug, Mildronate is continued to be taken as part of combination therapy at 0.5-1 g / day, using the entire dose once or dividing it into 2 doses. The course of treatment is 4-6 weeks. In chronic disorders of cerebral circulation, the drug is taken as part of a combination therapy by mouth at 0.5 g / day. The general course of therapy is 4-6 weeks. Repeated courses are possible after consulting a doctor (usually 2-3 times a year). With reduced performance, mental and physical overvoltage (including in athletes) is prescribed by mouth for 500 mg 2 times / day. The course of treatment is 10-14 days. If necessary, therapy is repeated after 2-3 weeks. Athletes are recommended to use 0.5-1 g 2 times / day before workouts. The duration of the course during the preparatory period is 14-21 days, during the competition period - 10-14 days. In case of withdrawal syndrome in chronic alcoholism (in combination with a specific therapy of alcoholism), the drug is administered orally 500 mg 4 times / day. The course of treatment is 7-10 days.
Side effects
Rarely - allergic reactions (redness and itching of the skin, skin rash, urticaria, angioedema), as well as dyspeptic phenomena, tachycardia, decreased or increased blood pressure, increased excitability. Very rare - eosinophilia, general weakness.
Overdose
Symptoms: decrease in blood pressure, accompanied by headache, tachycardia, dizziness and general weakness. Treatment: symptomatic treatment.
Interaction with other drugs
Mildronate enhances the action of coronarodilating agents, some antihypertensive drugs, cardiac glycosides. Mildronate can be combined with prolonged forms of nitrates, other antianginal drugs, anticoagulants and antiplatelet agents, antiarrhythmic drugs, diuretic and bronchodilator drugs. Due to the possible development of tachycardia and hypotension, caution should be exercised in combination with nitroglycerin (for sublingual use) and antihypertensive agents (especially alpha-blockers and short-acting forms of nifedipine).
special instructions
Patients with chronic liver and kidney diseases should be careful with long-term use of the drug. Use in pediatrics There is not enough data on the use of the drug Mildronate in children and adolescents under the age of 18 years. Impact on the ability to drive vehicles and control mechanisms Data on the adverse effects of Mildronate on the ability to drive vehicles and mechanisms are not available.